Canaccord Genuity Maintains a 'Buy' on Meridian Biosciences (VIVO); Illumigene Update
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.28 +1.90%
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 19
Rating Summary:
3 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 19
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Meridian Biosciences (NASDAQ: VIVO) price target of $25.00.
Analyst, Jeffrey Frelick, said, "An update from management reaffirms positive outlook of Illumigene and 2012 guidance and beyond...Group B strep launch going well. It appears that VIVO’s Group B Strep (GBS) molecular test is experiencing a good initial response in the market since its launch in early January...We initiate 2013 estimates for revenue of $210M (+16%) and EPS of $1.00 (up 20%)."
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $17.52 yesterday.
Analyst, Jeffrey Frelick, said, "An update from management reaffirms positive outlook of Illumigene and 2012 guidance and beyond...Group B strep launch going well. It appears that VIVO’s Group B Strep (GBS) molecular test is experiencing a good initial response in the market since its launch in early January...We initiate 2013 estimates for revenue of $210M (+16%) and EPS of $1.00 (up 20%)."
For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.
Shares of Meridian Biosciences closed at $17.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Erste Group Downgrades Rio Tinto (RIO) to Hold
- Erste Group Starts Freeport-McMoRan (FCX) at Buy
- Lucky Strike Entertainment (LUCK) PT Lowered to $10 at Texas Capital Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
